Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/27014
Title: Hepatitis delta: virological and clinical aspects
Authors: Vieira, Deusilene Souza
Souza, Luan Felipo Botelho
Vasconcelos, Mariana Pinheiro Alves
Santos, Alcione de Oliveira dos
Salcedo, Juan Miguel Villalobos
Affilliation: Fundação Oswaldo Cruz. Laboratório de Virologia Molecular. Porto Velho, RO, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisa em Medicina Tropical. Ambulatório de Hepatites Virais. Porto Velho, RO, Brasil / Programa de Pós-Graduação em Biologia Experimental. Porto Velho, RO, Brasil.
Fundação Oswaldo Cruz. Laboratório de Virologia Molecular. Porto Velho, RO, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisa em Medicina Tropical. Ambulatório de Hepatites Virais. Porto Velho, RO, Brasil / Programa de Pós-Graduação em Biologia Experimental. Porto Velho, RO, Brasil.
Instituto de Infectologia Emílio Ribas. São Paulo, SP, Brasil.
Fundação Oswaldo Cruz. Laboratório de Virologia Molecular. Porto Velho, RO, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisa em Medicina Tropical. Ambulatório de Hepatites Virais. Porto Velho, RO, Brasil / Programa de Pós-Graduação em Biologia Experimental. Porto Velho, RO, Brasil.
Fundação Oswaldo Cruz. Laboratório de Virologia Molecular. Porto Velho, RO, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisa em Medicina Tropical. Ambulatório de Hepatites Virais. Porto Velho, RO, Brasil / Programa de Pós-Graduação em Biologia Experimental. Porto Velho, RO, Brasil.
Abstract: There are an estimated 400 million chronic carriers of HBV worldwide; between 15 and 20 million have serological evidence of exposure to HDV. Traditionally, regions with high rates of endemicity are central and northern Africa, the Amazon Basin, eastern Europe and the Mediterranean, the Middle East and parts of Asia. There are two types of HDV/HBV infection which are differentiated by the previous status infection by HBV for the individual. Individuals with acute HBV infection contaminated by HDV is an HDV/HBV co-infection, while individuals with chronic HBV infection contaminated by HDV represent an HDV/HBV super-infection. The appropriate treatment for chronic hepatitis delta is still widely discussed since it does not have an effective drug. Alpha interferon is currently the only licensed therapy for the treatment of chronic hepatitis D. The most widely used drug is pegylated interferon but only approximately 25% of patients maintain a sustained viral response after 1 year of treatment. The best marker of therapeutic success would be the clearance of HBsAg, but this data is rare in clinical practice. Therefore, the best way to predict a sustained virologic response is the maintenance of undetectable HDV RNA levels.
Keywords: HDV
Virology
Clinical aspects
Issue Date: 2017
Publisher: BioMed Central
Citation: VIEIRA, D. S. et al. Hepatitis delta: virological and clinical aspects. Virology Journal, p. 1-15. 2017.
DOI: 10.1186/s12985-017-0845-y
Copyright: open access
Appears in Collections:RO - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
HDV revisão.pdf1.27 MBAdobe PDFView/Open


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.